复发难治性实体瘤NTRK靶向治疗新策略

doi:10.3760/cma.j.cn371439-20200212-00049

摘要/Abstract

摘要：

NTRK融合基因是儿童和成人多种肿瘤类型的致癌基因。由这些融合基因编码的融合蛋白具有原肌球蛋白相关激酶(TRK)酪氨酸激酶结构域,为肿瘤靶向治疗提供了新的靶点。在不区分肿瘤组织类型的前提下,NTRK融合阳性患者使用第一代TRK抑制剂(如拉罗替尼或恩曲替尼)治疗后,其有效率高达75%。大多数患者对第一代TRK抑制剂耐受性良好,长期使用TRK抑制剂可出现继发性耐药,其耐药机制通过NTRK激酶结构域突变介导。部分耐药突变可由第二代TRK抑制剂克服,包括目前处于临床试验的LOXO-195和TPX-0005。NTRK靶向治疗具有良好的疗效及安全性,是NTRK融合复发难治性实体瘤治疗的新选择。

关键词: 基因融合, 分子靶向治疗, 拉罗替尼, 恩曲替尼

Abstract:

NTRK gene fusions are oncogenic drivers of various paediatric and adult tumor types. The fusion proteins encoded by these fusion genes have tropomyosin related kinase (TRK) tyrosine kinase domains, which provides novel targets for tumor targeted therapy. The treatment of patients with NTRK fusion-positive cancers with a first-generation TRK inhibitor, such as larotrectinib or entrectinib, is associated with high response rate (>75%), regardless of tumor histology. The first-generation TRK inhibitors are well tolerated by most patients. Chronic use of TRK inhibitors can lead to secondary resistance, and the resistance is mediated by the acquisition of NTRK kinase domain mutations. Fortunately, certain resistance mutations can be overcome by second-generation TRK inhibitors, including LOXO-195 and TPX-0005 that are being explored in clinical trials. As for its good efficacy and safety, NTRK targeted therapy is a new choice for the treatment of relapsed refractory solid tumors with NTRK fusion.

Key words: Gene fusion, Molecular targeted therapy, Larotrectinib, Entrectinib

郝雪燕, 刘风玲. 复发难治性实体瘤NTRK靶向治疗新策略[J]. 国际肿瘤学杂志, 2020, 47(7): 423-427.

Hao Xueyan, Liu Fengling. A new strategy targeting NTRK in the treatment of recurrent and refractory solid tumors[J]. Journal of International Oncology, 2020, 47(7): 423-427.

参考文献 28

[1]	Kummar S, Lassen UN. TRK inhibition: a new tumor-agnostic treatment strategy[J]. Target Oncol, 2018,13(5):545-556. DOI: 10.1007/s11523-018-0590-1. pmid: 30276762
[2]	Davies AM, Horton A, Burton LE, et al. Neurotrophin-4/5 is a mammalian-specific survival factor for distinct populations of sensory neurons[J]. J Neurosci, 1993,13(11):4961-4967. DOI: 10.1523/JNEUROSCI.13-11-04961.1993. pmid: 8229208
[3]	Soppet D, Escandon E, Maragos J, et al. The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 areligands for the trkB tyrosine kinase receptor[J]. Cell, 1991,65(5):895-903. DOI: 10.1016/0092-8674(91)90396-g. doi: 10.1016/0092-8674(91)90396-g pmid: 1645620
[4]	Deinhardt K, Chao MV. Trk receptors[J]. Handb Exp Pharmacol, 2014,220:103-119. DOI: 10.1007/978-3-642-45106-5_5. pmid: 24668471
[5]	Laetsch TW, Hawkins DS. Larotrectinib for the treatment of TRK fusion solid tumors[J]. Expert Rev Anticancer Ther, 2019,19(1):1-10. DOI: 10.1080/14737140.2019.1538796. pmid: 30350734
[6]	Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types[J]. ESMO Open, 2016,1(2):e000023. DOI: 10.1136/esmoopen-2015-000023. pmid: 27843590
[7]	Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family proteins in cancer[J]. Pharmacol Ther, 2017,173:58-66. DOI: 10.1016/j.pharmthera.2017.02.006. doi: 10.1016/j.pharmthera.2017.02.006 pmid: 28174090
[8]	Bourgeois JM, Knezevich SR, Mathers JA, et al. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors[J]. Am J Surg Pathol, 2000,24(7):937-946. DOI: 10.1097/00000478-200007000-00005. doi: 10.1097/00000478-200007000-00005 pmid: 10895816
[9]	El Demellawy D, Cundiff CA, Nasr A, et al. Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement[J]. Pathology, 2016,48(1):47-50. DOI: 10.1016/j.pathol.2015.11.007. doi: 10.1016/j.pathol.2015.11.007 pmid: 27020209
[10]	Church AJ, Calicchio ML, Nardi V, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy[J]. Mod Pathol, 2018,31(3):463-473. DOI: 10.1038/modpathol.2017.127. doi: 10.1038/modpathol.2017.127 pmid: 29099503
[11]	Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma[J]. Nat Genet, 2014,46(5):444-450. DOI: 10.1038/ng.2938. doi: 10.1038/ng.2938 pmid: 24705251
[12]	Prasad ML, Vyas M, Horne MJ, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinomain Northeast United States[J]. Cancer, 2016,122(7):1097-107. DOI: 10.1002/cncr.29887. pmid: 26784937
[13]	Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas[J]. Nat Commun, 2014,5:3116. DOI: 10.1038/ncomms4116. doi: 10.1038/ncomms4116 pmid: 24445538
[14]	Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma[J]. Cancer Cell, 2002,2(5):367-376. DOI: 10.1016/s1535-6108(02)00180-0. doi: 10.1016/s1535-6108(02)00180-0 pmid: 12450792
[15]	Skalova A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity[J]. Am J Surg Pathol, 2010,34(5):599-608. DOI: 10.1097/PAS.0b013e3181d9efcc. doi: 10.1097/PAS.0b013e3181d9efcc
[16]	Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase Ⅰ dose-escalation study[J]. Ann Oncol, 2019,30(2):325-331. DOI: 10.1093/annonc/mdy539. doi: 10.1093/annonc/mdy539 pmid: 30624546
[17]	Bertrand T, Kothe M, Liu J, et al. The crystal structures of TRKA and TRKB suggest key regions forachieving selective inhibition[J]. J Mol Biol, 2012,423(3):439-453. DOI: 10.1016/j.jmb.2012.08.002. doi: 10.1016/j.jmb.2012.08.002 pmid: 22902478
[18]	Klein R, Jing SG, Nanduri V, et al. The TRK proto-oncogene encodes a receptor for nerve growth factor[J]. Cell, 1991,65(1):189-197. DOI: 10.1016/0092-8674(91)90419-y. doi: 10.1016/0092-8674(91)90419-y pmid: 1849459
[19]	Ricciuti B, Genova C, Crinò L, et al. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence[J]. Onco Targets Ther, 2019,12:3171-3179. DOI: 10.2147/OTT.S177051. doi: 10.2147/OTT.S177051 pmid: 31118670
[20]	Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children[J]. N Eng J Med, 2018,378(8):731-739. DOI: 10.1056/NEJMoa1714448. doi: 10.1056/NEJMoa1714448
[21]	Loxo Oncology. Vitrakvi®(Larotrectinib): US prescribing information[P/OL]. [2018-12-04]. .
[22]	Siena S, Doebele RC, Shaw AT, et al. Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: integrated analysis from three clinical trials[J]. J Clin Oncol, 2019,37(15_Suppl):3017. DOI: 10.1200/JCO.2019.37.15_suppl.3017. doi: 10.1200/JCO.2019.37.15_suppl.3017
[23]	Robinson GW, Gajjar AJ, Gauvain KM, et al. Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors[J]. J Clin Oncol, 2019,37(15_Suppl):10009. DOI: 10.1200/JCO.2019.37.15_suppl.10009. doi: 10.1200/JCO.2019.37.15_suppl.10009
[24]	Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase Ⅰ trials (ALKA-372-001 and STARTRK-1)[J]. Cancer Discov, 2017,7(4):400-409. DOI: 10.1158/2159-8290.CD-16-1237. doi: 10.1158/2159-8290.CD-16-1237 pmid: 28183697
[25]	Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors[J]. Cancer Discov, 2017,7(9):963-972. DOI: 10.1158/2159-8290.CD-17-0507. doi: 10.1158/2159-8290.CD-17-0507 pmid: 28578312
[26]	Zhai D, Deng W, Huang J, et al. TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resistance mechanisms by targeting SRC/FAK signaling[J]. Cancer Res, 2017,77(13 Suppl):3161. DOI: 10.1158/1538-7445.AM2017-3161.
[27]	Loxo Oncology. Loxo Oncology and illumina to partner on developing next-generation sequencing-based pan-cancer companion diagnostics[Z/OL]. [ 2018- 04- 10]. http://ir.loxooncology.com.
[28]	Chugai Pharmaceutical Co. Ltd. Chugai obtains approval of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for Rozlytrek[Z/OL]. [2019-06-27]. https://www.chugai-pharm.co.jp/english/news/detail/20190627120000_628.html.